论文部分内容阅读
贫血是恶性肿瘤常见的伴随疾病。肿瘤相关性贫血对患者存在较大的影响,可以降低患者生活质量、影响放化疗疗效等。促红细胞生成素(erythropoietin,EPO)是临床上治疗肿瘤相关性贫血的重要方式,其可提高患者血红蛋白水平、减少红细胞的输注、改善生活质量,但是使用EPO可以使血栓发生风险升高,关于是否影响患者总生存期、促进肿瘤转移等方面仍然存在争议。文章根据国内外相关文献,对EPO用于肿瘤相关性贫血患者的疗效及安全性进行总结。
Anemia is a common companion disease to malignant tumors. Tumor-related anemia has a greater impact on patients, can reduce the quality of life of patients, affecting the efficacy of radiotherapy and chemotherapy. Erythropoietin (EPO) is clinically an important way to treat tumor-associated anemia, which can increase hemoglobin level of patients, reduce the transfusion of red blood cells and improve the quality of life. However, the use of EPO can increase the risk of thrombosis. Whether it affects the overall survival of patients, promote tumor metastasis and other aspects are still controversial. The article summarizes the efficacy and safety of EPO in patients with tumor-associated anemia based on relevant literature at home and abroad.